InvestorsHub Logo
icon url

sunspotter

06/04/21 6:38 PM

#361592 RE: Lemoncat #361591

“There is much reason to believe that Brilacidin may outperform Remdesivir in the clinic. “

Actually there are few reasons to believe brilacidin will be more effective than remdesivir in the clinic, and several reasons to believe it will be more considerably toxic than remdesivir if used at a dose level likely to be sufficient to reach MICs for coronaviruses such as COVID-19.
icon url

loanranger

06/04/21 7:14 PM

#361594 RE: Lemoncat #361591

"Remdesivir is a prodrug which clearly did not match in vitro results when brought into the clinic. It really never has succeeded at treating any virus or other malady."

I don't disagree with sentence #1, but any chance you can explain how it ended up being a (if not THE) Standard of Care in the US (without mentioning any boogiemen)?

How can B be considered for an Emergency Use Authorization without being used in combination with some other drug when it isn't being tested alone? What might that other drug be?
icon url

BIzzy

06/04/21 10:06 PM

#361603 RE: Lemoncat #361591

All this just goes to support why randomized , double blind crossover studies are the gold standard..B meets that standard, we going to get gold